Query
Find articles
Pick a keyword, optionally a second one to combine it with (and, or, either but not both, or but not), then narrow the articles down by text, source and time range. Keywords update the results right away; filters apply with their button.
Query
How they overlap
Of the articles on each keyword in the last 7 days, with the same text and sources, how many also mention the other. Per lean: the share of its outlets' articles on vaccine that mention cancer.
35.7% of the 14 articles on vaccine also mention cancer, as do 8.2% of the 61 articles on cancer.
- Left-leaning4 of 9 articles
- 44.4%
- Least biased0 of 2 articles
- 0.0%
- Right-leaning1 of 3 articles
- 33.3%
Who picked it up when
TIME mentioned it first (Oct 22, 2026, 7:54 PM EDT). Right-leaning outlets followed 8 hours later. No least biased outlet mentioned it.
One row per source with a matching article, from the most left-leaning on top: a dot for each article, on a bar for each stretch of its coverage (a pause of more than 24 hours starts a new one). Hover or tap a dot for the headline, click it to read the article.
Source lean:leftcenterright
Source leans by Media Bias/Fact Check.
Results
5 articles mention vaccine and cancer in the last 7 days (Oct 20 to Oct 26).
| Article | |||
|---|---|---|---|
| NBC News | Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trialNBC News Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial. | 0.75 | |
| The New York Times | Melanoma Vaccine Ushers in New Hope for Cancer PatientsThe New York Times Beyond melanoma, scientists are studying cancer vaccines for glioblastoma, pancreatic cancer and more. | 0.85● | |
| New York Post | First-of-its-kind cancer vaccine helps reduce chances of melanoma patients’ tumors returning: studyNew York Post A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck. | 0.85● | |
| The Guardian | ‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial showsThe Guardian Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised way Get our new political email , free app or daily news podcast A personalised mRNA-based melanoma vaccine significantly reduces the risk of cancer recurrence or death within two years, new clinical trial results show. The vaccine, intismeran, is custom-made to target genetic mutations unique to an individual’s melanoma. It is the first individualised cancer vaccine to show positive results in a phase III clinical trial . Continue reading... | 0.65● | |
| TIME | A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%TIME The treatment is still experimental, but results from Moderna and Merck add scientific support for a vaccine-based approach to treating the cancer. | 0.85● |
Source leans by Media Bias/Fact Check.
Narrow further
Other keywords in the matching articles: the share of them that mention each, with the number of articles. The search icon searches for vaccine and that keyword instead of cancer, keeping the text, sources, source type and time range.
Coverage by source
The share of each source's stories in the last 7 days that match the query, from left to right. Sort the table to reorder the bars.
Source lean:leftcenterright
Source leans by Media Bias/Fact Check.
| The New York Times | 0.3% | 1 | 306 |
| TIME | 1.4% | 1 | 70 |
| NBC News | 0.5% | 1 | 197 |
| The Guardian | 0.1% | 1 | 710 |
| New York Post | 0.1% | 1 | 900 |
Coverage by lean
The share of stories that match the query, in the last 7 days, averaged over the outlets of each political lean with at least 3 stories. The groups differ in size, so a single outlet weighs more in the smaller ones.
- Left-leaning4 of 15 sources
- 0.2%
- Least biased0 of 8 sources
- 0.0%
- Right-leaning1 of 15 sources
- <0.1%
Lean index −3.5: covered more by left-leaning outlets
Each outlet at its MBFC bias score, from −10 (far left) to +10 (far right), as high as the share of its stories that match the query. The lean index is the average score of the outlets covering it, weighted by that share.
lean indexour sources' average (+0.4)leftcenterright
Bias scores by Media Bias/Fact Check.
Source leans based on ratings by Media Bias/Fact Check.